CN1886380B - 苯并咪唑化合物 - Google Patents

苯并咪唑化合物 Download PDF

Info

Publication number
CN1886380B
CN1886380B CN2004800354157A CN200480035415A CN1886380B CN 1886380 B CN1886380 B CN 1886380B CN 2004800354157 A CN2004800354157 A CN 2004800354157A CN 200480035415 A CN200480035415 A CN 200480035415A CN 1886380 B CN1886380 B CN 1886380B
Authority
CN
China
Prior art keywords
methyl
benzoglyoxaline
chloro
propoxy
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2004800354157A
Other languages
English (en)
Chinese (zh)
Other versions
CN1886380A (zh
Inventor
K·L·阿里恩蒂
J·G·布赖滕布赫
D·J·布扎德
J·P·爱德华兹
M·D·哈克
H·哈图亚
D·E·金德拉楚克
A·李
J·D·维纳布尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CN1886380A publication Critical patent/CN1886380A/zh
Application granted granted Critical
Publication of CN1886380B publication Critical patent/CN1886380B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Manufacturing & Machinery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ceramic Engineering (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Structural Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN2004800354157A 2003-09-30 2004-09-29 苯并咪唑化合物 Expired - Fee Related CN1886380B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50723603P 2003-09-30 2003-09-30
US60/507,231 2003-09-30
PCT/US2004/031855 WO2005044807A2 (en) 2003-09-30 2004-09-29 Benzoimidazole compounds

Publications (2)

Publication Number Publication Date
CN1886380A CN1886380A (zh) 2006-12-27
CN1886380B true CN1886380B (zh) 2010-12-22

Family

ID=38952593

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2004800354157A Expired - Fee Related CN1886380B (zh) 2003-09-30 2004-09-29 苯并咪唑化合物

Country Status (21)

Country Link
US (10) US7432378B2 (enExample)
EP (1) EP1673348B1 (enExample)
JP (1) JP2007508011A (enExample)
KR (1) KR20060097024A (enExample)
CN (1) CN1886380B (enExample)
AR (1) AR045955A1 (enExample)
AT (1) ATE427303T1 (enExample)
AU (1) AU2004286933B2 (enExample)
BR (1) BRPI0414918A (enExample)
CA (1) CA2540704A1 (enExample)
DE (1) DE602004020364D1 (enExample)
ES (1) ES2323178T3 (enExample)
HR (1) HRP20060126A2 (enExample)
IL (1) IL174677A0 (enExample)
NO (1) NO20061950L (enExample)
NZ (1) NZ546259A (enExample)
PT (1) PT1673348E (enExample)
RU (1) RU2006110561A (enExample)
TW (1) TW200526637A (enExample)
WO (1) WO2005044807A2 (enExample)
ZA (1) ZA200603411B (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045955A1 (es) * 2003-09-30 2005-11-16 Janssen Pharmaceutica Nv Compuestos benzoimidazolicos
JP5162236B2 (ja) 2004-03-25 2013-03-13 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ イミダゾール化合物
CA2572218C (en) 2004-06-30 2013-06-11 Janssen Pharmaceutica, N.V. Aryl-substituted benzimidazole and imidazopyridine ethers as anti-cancer agents
CN101248051B (zh) 2005-05-26 2013-07-17 泰博特克药品有限公司 制备4-[(1,6-二氢-6-氧代-2-嘧啶基)氨基]苯基氰的方法
AU2006264649A1 (en) * 2005-06-30 2007-01-11 Prosidion Limited GPCR agonists
EP1954287B2 (en) † 2005-10-31 2016-02-24 Merck Sharp & Dohme Corp. Cetp inhibitors
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
EP1961745A1 (en) * 2005-12-12 2008-08-27 Ono Pharmaceutical Co., Ltd. Bicyclic heterocyclic compound
ATE478067T1 (de) 2006-03-31 2010-09-15 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyridine und pyrazine als modulatoren des histamin-h4-rezeptors
AU2007235577B2 (en) * 2006-03-31 2011-09-15 Janssen Pharmaceutica N.V. Benzoimidazol-2-yl pyridines as modulators of the histamine H4 receptor
WO2007120690A2 (en) * 2006-04-10 2007-10-25 Janssen Pharmaceutica N.V. Combination histamine h1r and h4r antagonist therapy for treating pruritus
FR2903311B1 (fr) * 2006-07-10 2012-06-15 Centre Nat Rech Scient Utilisation de ligands du recepteur h4 de l'histamine pour proteger les progeniteurs hematopoietiques contre la toxicite hematologique des agents chimiotherapeutiques
US7985745B2 (en) 2006-10-02 2011-07-26 Abbott Laboratories Method for pain treatment
US8084466B2 (en) 2007-12-18 2011-12-27 Janssen Pharmaceutica Nv Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine H4 receptor
EP2077263A1 (en) 2008-01-02 2009-07-08 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Quinazolines and related heterocyclic compounds and their therapeutic use
UA100567C2 (ru) * 2008-06-12 2013-01-10 Янссен Фармацевтика Нв Использование антагонистов н4-гистаминовых рецепторов для лечения послеоперационных спаек
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
EA020090B1 (ru) * 2008-06-30 2014-08-29 Янссен Фармацевтика Нв Способ получения и рекристаллизации кристаллического гемитартрата бензоимидазол-2-илпиримидинового производного
BRPI0919816A2 (pt) * 2008-09-26 2019-09-24 Eisai R&D Man Co Ltd uso compostos benzoxazólicos no tratamento de malária
US8354400B2 (en) 2008-09-26 2013-01-15 Eisai R&D Co., Ltd. Benzoxazole compounds and methods of use
EP2201982A1 (en) 2008-12-24 2010-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Histamine H4 receptor antagonists for the treatment of vestibular disorders
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
IT1395137B1 (it) * 2009-08-05 2012-09-05 Spider Biotech S R L Nuovi peptidi antipatogeni
TW201111378A (en) 2009-09-11 2011-04-01 Bayer Schering Pharma Ag Substituted (heteroarylmethyl) thiohydantoins
CN102762572A (zh) 2010-02-01 2012-10-31 诺瓦提斯公司 作为CRF-1受体拮抗剂的吡唑并[5,1b]*唑衍生物
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
EP2531490B1 (en) 2010-02-02 2014-10-15 Novartis AG Cyclohexyl amide derivatives as crf receptor antagonists
EP2447263A1 (en) * 2010-09-27 2012-05-02 Bioprojet Benzazole derivatives as histamine H4 receptor ligands
UY34094A (es) 2011-05-27 2013-01-03 Novartis Ag Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina
DE102011122420B4 (de) 2011-12-24 2016-07-28 Volkswagen Aktiengesellschaft Verfahren zur Feststellung der Spannungsfreiheit in einem elektrischen Hochvolt-System und ein elektrisches Hochvolt-System
WO2013164790A1 (en) 2012-05-03 2013-11-07 Novartis Ag L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists
EP2671870A1 (en) 2012-06-05 2013-12-11 Bioprojet Novel (aza)benzhydryl ether derivatives, their process of preparation and their use as H4-receptor ligands for therapeutical applications
HUE039713T2 (hu) 2012-06-08 2019-02-28 Sensorion H4 receptor inhibitorok tinnitus kezelésére
JO3516B1 (ar) 2013-03-06 2020-07-05 Janssen Pharmaceutica Nv مُعدِّلات بنزإيميدازول-2-يل بيريميدين لمستقبل الهستامين h4
US11311013B2 (en) * 2018-05-22 2022-04-26 Nihon Nohyaku Co., Ltd. Benzimidazole compound or salt thereof, agricultural and horticultural insecticidal and acaricidal agent containing said compound, and method for using same

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0217700B1 (fr) * 1985-09-11 1994-03-30 Synthelabo Derives de benzimidazole, leur preparation et leur application en therapeutique
US6184235B1 (en) * 1996-08-14 2001-02-06 Warner-Lambert Company 2-phenyl benzimidazole derivatives as MCP-1 antagonists
CN1331682A (zh) * 1998-11-03 2002-01-16 巴斯福股份公司 取代的2－苯基苯并咪唑类,其制备和用途
WO2002072548A2 (en) * 2001-03-09 2002-09-19 Ortho-Mcneil Pharmaceutical, Inc. Heterocyclic compounds and their use as histamine h4 ligands.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19920936A1 (de) * 1999-05-07 2000-11-09 Basf Ag Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
AR045955A1 (es) * 2003-09-30 2005-11-16 Janssen Pharmaceutica Nv Compuestos benzoimidazolicos

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0217700B1 (fr) * 1985-09-11 1994-03-30 Synthelabo Derives de benzimidazole, leur preparation et leur application en therapeutique
US6184235B1 (en) * 1996-08-14 2001-02-06 Warner-Lambert Company 2-phenyl benzimidazole derivatives as MCP-1 antagonists
CN1331682A (zh) * 1998-11-03 2002-01-16 巴斯福股份公司 取代的2－苯基苯并咪唑类,其制备和用途
WO2002072548A2 (en) * 2001-03-09 2002-09-19 Ortho-Mcneil Pharmaceutical, Inc. Heterocyclic compounds and their use as histamine h4 ligands.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Jon Wright, et al.Discovery of selective dopamine D3 ligands: II.2-[4-[3-(4-aryl-1-piperazinyl)propoxy]phenyl]benzimidazolepartial agonists.Bioorganic & Medicinal Chemistry Letters5 21.1995,5(21),2547-2550. *

Also Published As

Publication number Publication date
BRPI0414918A (pt) 2006-11-07
US20090270366A1 (en) 2009-10-29
US20050070550A1 (en) 2005-03-31
TW200526637A (en) 2005-08-16
US7723359B2 (en) 2010-05-25
NZ546259A (en) 2009-05-31
US7705143B2 (en) 2010-04-27
AR045955A1 (es) 2005-11-16
ZA200603411B (en) 2007-07-25
US20090270611A1 (en) 2009-10-29
US7662966B2 (en) 2010-02-16
EP1673348A2 (en) 2006-06-28
WO2005044807A3 (en) 2005-08-11
US20090275748A1 (en) 2009-11-05
HRP20060126A2 (en) 2008-05-31
AU2004286933A1 (en) 2005-05-19
ATE427303T1 (de) 2009-04-15
JP2007508011A (ja) 2007-04-05
US20090264647A1 (en) 2009-10-22
IL174677A0 (en) 2006-08-20
US20090270613A1 (en) 2009-10-29
CN1886380A (zh) 2006-12-27
NO20061950L (no) 2006-06-29
US7723526B2 (en) 2010-05-25
US20090247508A1 (en) 2009-10-01
US20090264645A1 (en) 2009-10-22
CA2540704A1 (en) 2005-05-19
AU2004286933B2 (en) 2010-11-18
PT1673348E (pt) 2009-05-11
DE602004020364D1 (de) 2009-05-14
US20090281307A1 (en) 2009-11-12
US20090264646A1 (en) 2009-10-22
US7705149B2 (en) 2010-04-27
ES2323178T3 (es) 2009-07-08
EP1673348B1 (en) 2009-04-01
WO2005044807A2 (en) 2005-05-19
US7432378B2 (en) 2008-10-07
US7723527B2 (en) 2010-05-25
RU2006110561A (ru) 2007-10-10
KR20060097024A (ko) 2006-09-13

Similar Documents

Publication Publication Date Title
JP4767857B2 (ja) ベンゾイミダゾール化合物
US7705149B2 (en) Benzoimidazole compounds
CN101022728B (zh) 咪唑化合物
CN105683181A (zh) 新的氨基嘧啶衍生物
WO2005085212A1 (ja) 置換ピリミジン誘導体
MXPA06003579A (en) Benzoimidazole compounds
HK1102020B (en) Imidazole compounds

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20101222

Termination date: 20210929

CF01 Termination of patent right due to non-payment of annual fee